Loading
A phase 2 trial of camrelizumab, gemcitabine, oxaliplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, active and no longer recruiting.
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT05451290 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 30 participants, started 2022-11-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur. Conditions listed: Advanced Biliary Tract Carcinoma. Sites: China. No results are recorded here; the registry entry is the source.
Shares Camrelizumab, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Tegafur, gimeracil and oteracil (S-1), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Tegafur, gimeracil and oteracil (S-1), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.